首页> 外文期刊>Hormone research >Clinical and subclinical ACTH-independent macronodular adrenal hyperplasia and aberrant hormone receptors.
【24h】

Clinical and subclinical ACTH-independent macronodular adrenal hyperplasia and aberrant hormone receptors.

机译:临床和亚临床不依赖ACTH的大结节性肾上腺增生和异常激素受体。

获取原文
获取原文并翻译 | 示例
       

摘要

ACTH-independent macronodular adrenal hyperplasia (AIMAH) is a very rare cause of endogenous Cushing's syndrome (CS). In this review, the clinical characteristics, the pathophysiology, and the management of AIMAH are described. AIMAH typically presents with overt CS, but subclinical oversecretion of cortisol has been increasingly described. The diagnosis is suspected by adrenal nodular enlargement on conventional imaging following the demonstration of ACTH-independent hypercortisolism. Final diagnosis is established by histological examination of the adrenal tissue. Bilateral adrenalectomy is the treatment of choice but unilateral adrenalectomy has been proposed in selected cases. In patients with subclinical CS, the decision to treat should be individualized. The pathophysiology of this condition has begun to be elucidated in recent years. Diverse aberrant membrane-bound receptors expressed in a non-mutated form in the adrenal gland have been found to be implicated in the regulation of steroidogenesisin AIMAH. When systematically screened, most patients with AIMAH and CS or subclinical CS exhibit an in vivo aberrant cortisol response to one or various ligands suggesting the presence of aberrant adrenal receptors. A protocol designed to screen patients for the presence of these aberrant receptors should be undertaken in all patients with AIMAH. The identification of these receptors provides the potential for novel pharmacological therapies by suppressing the endogenous ligands or blocking the receptor with specific antagonists.
机译:独立于ACTH的大结节性肾上腺皮质增生(AIMAH)是内源性库欣综合征(CS)的罕见原因。在这篇综述中,描述了AIMAH的临床特征,病理生理和管理。 AIMAH通常表现为明显的CS,但是越来越多地描述了亚临床皮质醇的过度分泌。在不依赖ACTH的皮质醇过多症表现出来后,常规影像学发现肾上腺结节增大可怀疑诊断。最终诊断通过肾上腺组织的组织学检查确定。选择双侧肾上腺切除术是治疗选择,但已建议在某些情况下进行单侧肾上腺切除术。在亚临床CS患者中,治疗决定应个体化。近年来已经阐明了这种病症的病理生理学。已经发现在肾上腺中以非突变形式表达的多种异常的膜结合受体与AIMAH中类固醇生成的调节有关。当进行系统筛选时,大多数患有AIMAH和CS或亚临床CS的患者表现出对一种或多种配体的体内异常皮质醇反应,表明存在异常的肾上腺受体。对所有患有AIMAH的患者均应采取旨在筛选患者是否存在这些异常受体的方案。这些受体的鉴定通过抑制内源性配体或用特异性拮抗剂阻断受体,为新型药物治疗提供了潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号